The stock of Mustang Bio, Inc. (NASDAQ:MBIO) is now priced at $3.36 and the shares are 0.28 points up or 9.09% higher compared to its previous closing price of $3.08. The stock had 1.926 million contracts set over the past session. MBIO shares’ daily volume is compared to its average trading volume at 0.952 million shares. However, it has a float of 31.49 million and although its performance was 5% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the MBIO share price recently placing at $3.04 to $3.42. However, some brokerage firms have priced the stock below the average, including one that has called $7.

The shorts are running away from the Mustang Bio, Inc. stock, with the latest data on short interest released on July 15, 2020, showing that short interest numbers in the MBIO shares have declined. Short interest in the stock represents just 1.72% of its float, but the volume has dropped by -54328. The volume of shorted shares dropped to 541573 from 595901 shares over the last two weeks. The average intraday trading volume has been 683263 shares, which means that days to cover moved to roughly 1.

In the last trading session, Mustang Bio, Inc. (NASDAQ:MBIO) raised by $0.16 over the week and gained $0.23 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $4.85. The stock recorded its established 52-week high on 06/10/20.

Since 03/13/20, the stock has traded to a low of $1.78 at 88.76%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge.

Looking at current readings, Mustang Bio, Inc.’s two-week RSI is 51.92. This suggests that the stock is neutral at the moment and that MBIO shares’ price movement remains stable. The stochastic readings are equally revealing at 24.56% meaning the MBIO share price is currently in overbought territory.

The technical chart shows that the MBIO stock will likely settle at between $3.51 and $3.65 per share. However, if the stock dips below $3.13, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $2.89.

Currently, the stock is trading in the red of MACD, with a reading of -0.04. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Maxim Group assigned MBIO a rating of Overweight in their intiating review released on November 20. H.C. Wainwright analysts see the stock as a Buy with a target price of $7 in a flash note released to investors on August 13 initiating covering the stock. Cantor Fitzgerald analysts see the stock as Overweight when the analysts initiated the share price coverage on June 21, placing it at $7.

The average rating for the MBIO equity is 1.67 and is currently gathering a bullish momentum. Of 3 analysts tracking Mustang Bio, Inc. polled by Reuters, 0 rated MBIO as a hold. The remaining 3 analysts were split evenly. However, the split wasn’t equal as a majority (3) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.